How much does Opdivo cost?
The cost for Opdivo intravenous solution (10 mg/mL) is around $1,189 for a supply of 4 milliliters, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans. This Opdivo price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
What kind of drug is Opdivo?
Opdivo Prices, Coupons and Patient Assistance Programs. Opdivo (nivolumab) is a member of the Anti-PD-1 monoclonal antibodies drug class and is commonly used for Colorectal Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, and others.
What is the Opdivo PAP?
Patient Assistance Programs for Opdivo Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or discounted medicines to low income or uninsured and under-insured people who meet specific guidelines. Eligibility requirements vary for each program. Provider: HealthWell Foundation Copay Program
See more
Why is BMY stock dropping?
Bristol Myers Stock Drops After 'Fairly Uninspiring' Earnings Beat. The company effectively lowered its sales guidance for 2022 slightly, saying it now expects $46 billion in sales for the year.
Is BMY a buy today?
No, in September 2021, BMY stock isn't a buy.
How much is Bristol Myers stock worth?
$ 76.00CloseChgChg %$75.651.642.22%
Is Bristol Myers Squibb publicly traded?
Bristol-Myers Squibb's shares traded at over $55 per share, and its market capitalization was valued at over US$81.6 billion in October 2018.
Is Merck a buy or sell?
Is Merck Stock A Buy Now? Based on CAN SLIM rules for investing, Merck stock is not a buy right now. Shares fell well below their entry and triggered a sell rule. Investors should wait for a new base to form with a possible new buy point of 95.02.
Is Bristol-Myers Squibb part of Pfizer?
Bristol-Myers Squibb will make an upfront payment of $50 million to Pfizer as part of this agreement. The companies will share all development and commercialization expenses along with profits/losses on a 60%-40% basis, with Pfizer assuming the larger share of both expenses and profit/losses.
What did Bristol Myers stock close at today?
Performance OutlookPrevious Close74.01Open74.82Bid75.87 x 1000Ask75.76 x 1200Day's Range74.29 - 75.883 more rows
What drugs does Bristol Myers Squibb make?
Our medicinesABECMA® (idecabtagene vicleucel) ... ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) ... AZACTAM® (aztreonam for injection, USP) ... BREYANZI® (lisocabtagene maraleucel) ... BARACLUDE® (entecavir) ... CAMZYOSTM (mavacamten) ... DROXIA® (hydroxyurea) ... ELIQUIS® (apixaban)More items...•
What did Dow Chemical stock close at today?
$51.01Stock Quote (U.S.: NYSE) | MarketWatch....$ 51.11.CloseChgChg %$51.01-0.37-0.72%
Does Bristol-Myers pay a dividend?
In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable June 1, 2022, to stockholders of record at the close of business on May 10, 2022.
Is BMS a good company?
BMS is a great company with many opportunities for the right people who meet the qualifications and style of pharmaceutical research and development company.
How big is BMS?
Bristol-Myers Squibb (BMS) is one of the largest pharmaceutical companies in the world, with 25,000 employees and $19.4 billion in revenue in 2016.
Will BMY stock go up?
The 17 analysts offering 12-month price forecasts for Bristol-Myers Squibb Co have a median target of 83.00, with a high estimate of 92.00 and a low estimate of 61.00. The median estimate represents a +11.20% increase from the last price of 74.64.
Is BMY undervalued?
That said, BMY stock looks undervalued at its current levels of $55. Going by our Bristol Myers Squibb Valuation of $79 per share, based on $7.52 expected adjusted EPS and around 10x P/E multiple for 2021, there is an upside potential of 45% from its current levels.
Is BMY a good stock to buy Zacks?
Bristol-Myers currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the same space is Alkermes ( ALKS Quick Quote ALKS - Free Report) which sports a Zacks Rank #1 (Strong Buy) at present.
Is Bristol Myers Squibb a good company?
Bristol-Myers Squibb has an overall rating of 4.1 Average Rating out of 5, based on over 196 Bristol-Myers Squibb Review Ratings left anonymously by Bristol-Myers Squibb employees, which is 5% higher than the average rating for all companies on CareerBliss.
Pricing Opdivo In China
Immuno-Oncology Rivals
There's a lot of guesswork surrounding Opdivo pricing in China, portfolio manager Brad Loncar told IBD in an interview. Loncar runs several biotech stock indexes including the Cancer Immunotherapy Sector Index and the Loncar China BioPharma Index.
Bristol Is First To China Approval
Opdivo is one of Bristol's top two moneymakers. It's an immuno-oncology drug competing against Keytruda from Dow Jones component Merck ( MRK ).
Burgeoning Biotech In China
Opdivo was the first immuno-oncology drug to gain approval in China. Physicians can prescribe it to some patients who've already undergone chemotherapy.